Compile Data Set for Download or QSAR
Report error Found 27 Enz. Inhib. hit(s) with all data for entry = 7687
TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210759(US9290454, 4.4)
Affinity DataKi:  5.16nM ΔG°:  -51.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210749(US9290454, 3.1)
Affinity DataKi:  5.79nM ΔG°:  -51.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210750(US9290454, 3.2)
Affinity DataKi:  6.50nM ΔG°:  -50.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210764(US9290454, 7.2)
Affinity DataKi:  7.79nM ΔG°:  -50.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210751(US9290454, 3.3)
Affinity DataKi:  8.20nM ΔG°:  -50.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210752(US9290454, 3.4)
Affinity DataKi:  8.84nM ΔG°:  -49.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210760(US9290454, 5.1)
Affinity DataKi:  10.2nM ΔG°:  -49.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210767(US9290454, 8.1)
Affinity DataKi:  10.9nM ΔG°:  -49.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210765(US9290454, 7.3)
Affinity DataKi:  12.7nM ΔG°:  -48.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210753(US9290454, 3.5)
Affinity DataKi:  13.1nM ΔG°:  -48.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210757(US9290454, 4.2)
Affinity DataKi:  13.6nM ΔG°:  -48.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210766(US9290454, 7.4)
Affinity DataKi:  14.8nM ΔG°:  -48.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210768(US9290454, 8.2)
Affinity DataKi:  14.8nM ΔG°:  -48.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210769(US9290454, 8.3)
Affinity DataKi:  17.0nM ΔG°:  -48.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210771(US9290454, 8.5)
Affinity DataKi:  17.2nM ΔG°:  -48.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210772(US9290454, 8.6)
Affinity DataKi:  17.3nM ΔG°:  -48.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210754(US9290454, 3.7 | US9290454, 3.6)
Affinity DataKi:  18.7nM ΔG°:  -47.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210758(US9290454, 4.3)
Affinity DataKi:  20.7nM ΔG°:  -47.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210763(US9290454, 7.1)
Affinity DataKi:  21.5nM ΔG°:  -47.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210756(US9290454, 4.1)
Affinity DataKi:  22.5nM ΔG°:  -47.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210762(US9290454, 6.2)
Affinity DataKi:  25.4nM ΔG°:  -47.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210770(US9290454, 8.4)
Affinity DataKi:  37.2nM ΔG°:  -46.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210746(US9290454, 1.1)
Affinity DataKi:  37.7nM ΔG°:  -45.9kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210747(US9290454, 1.2)
Affinity DataKi:  49.0nM ΔG°:  -45.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210761(US9290454, 6.1)
Affinity DataKi:  79.1nM ΔG°:  -43.9kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210754(US9290454, 3.7 | US9290454, 3.6)
Affinity DataKi:  363nM ΔG°:  -39.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent

TargetProstaglandin D2 receptor 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM210748(US9290454, 2.1)
Affinity DataKi:  4.92E+3nM ΔG°:  -32.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding was performed using filtration or scintillation proximity assay (SPA) technology. SPA assays were done at room temperature in 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2017
Entry Details
US Patent